BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 23887973)

  • 1. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N
    Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting continued androgen receptor signaling in prostate cancer.
    Massard C; Fizazi K
    Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration-resistant prostate cancer: adaptive responses in the androgen axis.
    Egan A; Dong Y; Zhang H; Qi Y; Balk SP; Sartor O
    Cancer Treat Rev; 2014 Apr; 40(3):426-33. PubMed ID: 24139549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor antagonists in castration-resistant prostate cancer.
    Rathkopf D; Scher HI
    Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients with castration-resistant disease.
    Pezaro C; Omlin A; Lorente D; de Bono J
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1243-60, ix. PubMed ID: 24188261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
    Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC
    Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.
    Molina A; Belldegrun A
    J Urol; 2011 Mar; 185(3):787-94. PubMed ID: 21239012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel drugs targeting the androgen receptor pathway in prostate cancer.
    Mateo J; Smith A; Ong M; de Bono JS
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
    Attard G; Richards J; de Bono JS
    Clin Cancer Res; 2011 Apr; 17(7):1649-57. PubMed ID: 21372223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transcriptional programme of the androgen receptor (AR) in prostate cancer.
    Lamb AD; Massie CE; Neal DE
    BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.